Kyowa Kirin Co., Ltd.
KYKOF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.76B
Close$
$13.43
19.8% downside
Current Fair Value
19.8% downsideOvervalued by 19.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8.76 Billion |
|---|---|
| Enterprise Value | $-232,359,231,820.00 |
| Annual dividend | $0.42 |
| Dividend yield | 2.72% |
| Earnings per Share | $128.18 |
| Beta | 0.42 |
| Outstanding Shares | 523,557,000 |
Return
| Return on Equity | 8.94% |
|---|---|
| Return on Assets | 7.24% |
| Return on Invested Capital | 13.72% |
Valuation & Multiples
| P/E Ratio | 15.86 |
|---|---|
| PEG | 19.41 |
| Price to Sales | 0.02 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 1.98 |
| Enterprise Value to EBIT | 8.12 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS Estimate
$0.25
Consensus analyst estimateRevenue Estimate
$796.43 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 10, 2027
EPS Estimate
$0.35
Consensus analyst estimateRevenue Estimate
$895.08 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Kyowa Kirin Co., Ltd.
5,161 employees
CEO: Abdul Hafeez Mullick
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, c...